Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Gynecologic Oncology|May 6, 2017
SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expressionGulden Menderes, Elena Bonazzoli, Stefania Bellone, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|February 12, 2015
Dacomitinib (PF-00299804), a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor, demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitroLiancheng Zhu, Salvatore Lopez, Stefania Bellone, et al.
Gynecologic Oncology Reports|November 18, 2020
Prescribed medical cannabis in women with gynecologic malignancies: A single-institution survey-based studyEmily M Webster, Ghanshyam S Yadav, Stefan Gysler, et al.
British Journal of Cancer|June 29, 2016
Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivoEmiliano Cocco, Salvatore Lopez, Jonathan Black, et al.
Molecular Cancer Therapeutics|June 4, 2016
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu ExpressionJonathan Black, Gulden Menderes, Stefania Bellone, et al.
Gynecologic Oncology|November 30, 2016
Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitroStefania Bellone, Eliana Bignotti, Silvia Lonardi, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 30, 2016
Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transitionSiming Zhao, Stefania Bellone, Salvatore Lopez, et al.
Pageof 5